Anixa Biosciences Inc (ANIX) 10K Annual Reports & 10Q SEC Filings

Cover - USD ($)	12 Months Ended
Cover - USD ($)	Oct. 31, 2022	Jan. 05, 2023	Apr. 29, 2022
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Oct. 31, 2022
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--10-31
Entity File Number	001-37492
Entity Registrant Name	ANIXABIOSCIENCES, INC.
Entity Central Index Key	0000715446
Entity Tax Identification Number	11-2622630
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	3150Almaden Expressway
Entity Address, Address Line Two	Suite 250
Entity Address, City or Town	SanJose
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	95118
City Area Code	(408)
Local Phone Number	708-9808
Title of 12(b) Security	Common Stock, $0.01 par value
Trading Symbol	ANIX
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 93,235,194
Entity Common Stock, Shares Outstanding		30,920,792
Documents Incorporated by Reference [Text Block]	NONE
ICFR Auditor Attestation Flag	false
Auditor Firm ID	200
Auditor Name	HASKELL& WHITE LLP
Auditor Location	Irvine,California

Please wait while we load the requested 10-K report or click the link below:

https://last10k.com/sec-filings/report/715446/000149315223000346/form10-k.htm

View differences made from one year to another to evaluate Anixa Biosciences Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ) — *Sample 10-K Year-over-Year (YoY) Comparison*

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were ~~removed~~ , added and changed by Anixa Biosciences Inc.

Continue

Assess how Anixa Biosciences Inc's management team is paid from their Annual Proxy

Anixa Biosciences Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2023 10-K Annual Report includes:

Voting Procedures
Board Members
Executive Team
Salaries, Bonuses, Perks
Peers / Competitors

Continue

Rating
Learn More

Filter Sentiment:

All

Positive

Negative

Filter Category:

All

Revenue

Financial

Other

Filter Subcategory:

All

Product

Cash Flow

Expense

Other

Inside Anixa Biosciences Inc's 10-K Annual Report:

Other - Other Highlight
The net loss attributable to noncontrolling interest, representing Wistar's 5% ownership interest in Certainty's net loss, increased by approximately $2,000 to approximately $176,000 in fiscal year 2022, from approximately $174,000 in fiscal year 2021, as Certainty's net loss increased.

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Material Contracts, Statements, Certifications & more

Anixa Biosciences Inc provided additional information to their SEC Filing as exhibits

Exhibit 23.1: Consents Of Experts And Counsel

Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 32.1: Section 1350 Certification

Exhibit 32.2: Section 1350 Certification

Ticker: ANIX
CIK: 715446
Form Type: 10-K Annual Report
Accession Number: 0001493152-23-000346
Submitted to the SEC: Wed Jan 04 2023 4:59:57 PM EST
Accepted by the SEC: Wed Jan 04 2023
Period: Monday, October 31, 2022
Industry: Medical Laboratories

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/anix/0001493152-23-000346.htm

Anixa Biosciences Inc (ANIX) SEC Filing 10-K Annual Report for the fiscal year ending Monday, October 31, 2022

SEC Filings

ANIX Valuations

ANIX Annual Reports

ANIX Quarterly Reports

ANIX Corporate News